Amgen (AMGN) is facing mixed investment behaviors alongside varied growth potential. There's a recent decrease in
stock positions by several firms, including Y Intercept Hong Kong Ltd, Choreo LLC, and Legato Capital Management LLC. Rep. Jefferson Shreve and Gries Financial also sold off considerable shares. Simultaneously, firms like SYM Financial Corp, Skandinaviska Enskilda Banken AB, and Brookwood Investment Group made substantial new investments in Amgen. The
earnings growth of Amgen has been below the 10% YoY shareholder returns for the last three years. Several analysts predict substantial growth potential in
Pharma Stocks for Amgen, citing it as a potential 'Hidden Gem' in 2025. Market response to recent declines has been negative but the stock is still considered a good buy by many analysts. Amgen has announced
positive results from Phase 3 study of Bemarituzumab and introduced full results of MariTide's Phase 2 study. On the other hand, the company's stock fell sharply after Novo Nordisk reported successful trials for their weight loss drug. Analysts from UBS Group and Bank of America have indicated expectations of a rise in
stock prices.
Amgen AMGN News Analytics from Mon, 24 Mar 2025 07:00:00 GMT to Sat, 26 Jul 2025 17:45:19 GMT -
Rating 3
- Innovation 6
- Information 8
- Rumor 2
